{
    "clinical_study": {
        "@rank": "20037", 
        "arm_group": [
            {
                "arm_group_label": "Racecadotril 10mg suspension", 
                "arm_group_type": "Experimental", 
                "description": "single oral dose"
            }, 
            {
                "arm_group_label": "Racecadotril 30mg suspension", 
                "arm_group_type": "Experimental", 
                "description": "single oral dose"
            }, 
            {
                "arm_group_label": "Racecadotril 60mg suspension", 
                "arm_group_type": "Experimental", 
                "description": "single oral dose"
            }, 
            {
                "arm_group_label": "Racecadotril 60mg granules", 
                "arm_group_type": "Active Comparator", 
                "description": "single oral dose"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the Racecadotril pharmacokinetic linearity after single oral administration\n      of 10, 30 and 60 mg as a suspension.\n\n      To evaluate the comparative bioavailability of the new Racecadotril formulation (suspension)\n      versus the reference sachet formulation (granules)"
        }, 
        "brief_title": "Racecadotril Suspension Linearity Study & Comparative Bioavailability Versus Granules", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Male Volunteers", 
        "detailed_description": {
            "textblock": "This is a single center, open-label, single oral dose, 4-period cross-over study to assess\n      the bioequivalence of a new formulation (suspension) in healthy male volunteers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male,\n\n          -  18 to 45 years old,\n\n          -  be certified as normal by a comprehensive clinical assessment (detailed medical\n             history and a complete physical examination), arterial blood pressure (BP), heart\n             rate (HR), an ECG and laboratory investigations (haematological, blood chemistry\n             tests, urinalysis), the results of which are within the normal range and/ or judged\n             by the investigator as clinically acceptable for healthy subjects,\n\n          -  Body Mass Index (BMI) between 18 and 28 kg/m2.\n\n        Exclusion Criteria:\n\n          -  History of cardiovascular, pulmonary gastro-intestinal, hepatic, renal, metabolic,\n             haematological, neurological, psychiatric, systemic, or infectious disease.\n\n          -  Any other condition which, in the opinion of the Investigator, would jeopardize the\n             safety of the subject or impact the validity of the study results.\n\n          -  Subject has used any drug including OTC products two weeks before the scheduled\n             administration of study drug, except paracetamol (maximum 1g/day)."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "53", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01948011", 
            "org_study_id": "P13-01 / BP0.52", 
            "secondary_id": "2013-002746-36"
        }, 
        "intervention": [
            {
                "arm_group_label": "Racecadotril 60mg granules", 
                "description": "Racecadotril suspension at 10, 30 and 60mg. Single oral dose.", 
                "intervention_name": "Racecadotril suspension", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Racecadotril 10mg suspension", 
                    "Racecadotril 30mg suspension", 
                    "Racecadotril 60mg suspension"
                ], 
                "description": "Racecadotril granules at 60mg. Single oral dose.", 
                "intervention_name": "Racecadotril granules", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetorphan", 
                "Thiorphan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gi\u00e8res", 
                    "country": "France", 
                    "zip": "38610"
                }, 
                "name": "Eurofins Optimed"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "4", 
        "official_title": "Study of the Racecadotril Linearity After Single Administrations of 10, 30 and 60 mg of a New Racecadotril Formulation (Suspension) by Oral Route and Evaluation of the Comparative Bioavailability of This New Formulation Versus the Sachet Formulation (Granules) After a 60 mg Single Oral Administration in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "EUROFINS OPTIMED", 
            "last_name": "Yves Donazzolo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Several blood sample will be collected at each period to investigate the racecadotril pharmacokinetic linearity and to evaluate the comparative bioavalibility.\n4-period, cross over, single oral dose at each period.", 
            "measure": "Bio-equivalence", 
            "safety_issue": "No", 
            "time_frame": "Total study duration per subject should be 6 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01948011"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bioprojet", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bioprojet", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}